CAS
NVAX icon

Coppell Advisory Solutions’s Novavax NVAX Stock Holding History

Coppell Advisory Solutions’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27
Closed -$214 – 1342
2024
Q4 		$214 Hold
27
– – ﹤0.01% 1830
2024
Q3 		$359 Hold
27
– – ﹤0.01% 1687
2024
Q2 		$342 Buy
+27
New +$272 ﹤0.01% 1615

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coppell Advisory Solutions's NVAX Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Novavax (NVAX) in Q1 2025, closing a stake of 27 shares — an estimated $214 sold.

Coppell Advisory Solutions first reported a position in NVAX in Q2 2024 and held it in 3 quarters. The position peaked at $359 in Q3 2024. 245 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 27 Novavax shares in Q1 2025, an estimated $214.
  • Coppell Advisory Solutions first reported a position in Novavax in Q2 2024 and held it in 3 quarters.
  • Coppell Advisory Solutions's Novavax position peaked at $359 in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.